Basit öğe kaydını göster

dc.contributor.authorYenidunya Yalin, Gulsah
dc.contributor.authorCiftci Dogansen, Sema
dc.contributor.authorYarman, Sema
dc.date.accessioned2019-05-14T12:54:30Z
dc.date.available2019-05-14T12:54:30Z
dc.date.issued2018
dc.identifier.issn1301-2193
dc.identifier.urihttp://www.turkjem.org/uploads/pdf/812692612877334.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3282
dc.description.abstractProlactinomas are the most common hormone-secreting pituitary adenomas. Prolactinomas account for nearly 30-40 percent of all the pituitary adenomas. Although it affects individuals over a wide age range, it is more common in 20-40-year-old female patients, who are in their reproductive age. Prolactinomas may cause hypogonadism, menstrual cycle dysfunction (oligomenorrhea or amenorrhea) and infertility (luteal phase abnormalities or anovulation) in premenopausal women. When pregnancy is excluded, hyperprolactinemia in approximately 10 to 20 percent of the patients results in amenorrhea. Women with untreated pro-lactinomas are generally unable to achieve pregnancy, as the hyperprolactinemia affects the pulsatility of gonadotropin-releasing hormone (GnRH) and diminishes follicle-stimulating hormone (FSH) as well as luteinizing hormone (LH) secretion. The sum of these effects induces amenorrhea, infertility, and hypogonadism, thereby posing difficulties in fertility. Therefore, in most women prolactinoma is diagnosed prior to conception. However, ovulation and fertility usually improve after proper diagnosis and treatment of prolactinoma. Therefore, during the surveillance of these patients, the onset of pregnancy is a common phenomenon. Management of these pregnancies may sometimes be challenging and require a multidisciplinary approach involving an endocrinologist, a gynecologist, a radiologist and an experienced neurosurgeon in order to achieve the best outcomes both for the patient as well the infant. In this report, the authors aim to summarize the consensus statements and the current guidelines for clinical practice.en_US
dc.language.isoengen_US
dc.relation.isversionof10.25179/tjem.2017-57578en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProlactinomaen_US
dc.subjectPregnancyen_US
dc.subjectDopamine agonistsen_US
dc.titleReview of Clinical Recommendations on Prolactinoma and Pregnancyen_US
dc.typereviewen_US
dc.relation.journalTURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISMen_US
dc.identifier.volume22en_US
dc.identifier.issue1en_US
dc.identifier.startpage54en_US
dc.identifier.endpage56en_US
dc.identifier.wos000429745000010en_US
dc.identifier.scopus2-s2.0-85044759731en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster